Discover why psoriasis treatments may lose effectiveness and explore alternatives. Learn about the potential of biologics, systemic therapies, and more to manage symptoms.

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

A Johnson & Johnson banner is displayed on the front of the NYSE in New York (Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the ...

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...

Real-world Danish registry data show that biologic drug survival in psoriasis differs between biologic-naive and ...

Alumis, a clinical-stage biopharmaceutical company, has announced two phase 3 trials of its TYK2 inhibitor envudeucitinib met their co-primary endpoints in adults with moderate to severe plaque ...

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.

Psoriasis can increase skin infection risk due to effects from the condition and its treatments. Learn about potential infections, symptoms, and preventive measures.